Zeo ScientifiX Posts 89% Revenue Growth, but Auditor Raises Going Concern Doubt
ZEOX sits 18% above its 52-week low of $0.97.
Summary
Zeo ScientifiX filed its transition 10-K showing 89% revenue growth to $5.9 million, but a $5.0 million net loss and an auditor's going concern warning. The filing also reveals material internal control weaknesses and several related-party deals.
Key Events · Earnings and Guidance · ZEOX
-
Going Concern Warning
Auditor Weinberg & Company expressed substantial doubt about Zeo ScientifiX's ability to continue as a going concern, citing a $5.07 million net loss and $383,000 of cash used in operations during the eight-month transition period.
-
Revenue Growth
Revenue increased 89.4% to $5.87 million for the eight months ended June 30, 2026, driven by higher-concentration allogenic biologic product sales following new state stem cell laws.
-
Material Weaknesses
Management disclosed material weaknesses in internal control over financial reporting, including limited segregation of duties and insufficient IT access controls due to the company's small size.
-
Related-Party Transactions
The company formed Serephon LLC with CEO Ian Bothwell, CMO Dr. George Shapiro, and principal shareholder Greyt Ventures, consolidating it as a variable interest entity. Serephon generated $431,000 in revenue and $72,000 net profit during the period.
Analysis · ZEOX · Life Sciences
Revenue nearly doubled to $5.9 million in Zeo ScientifiX's transition report, yet the company still lost $5.0 million and its auditor has expressed substantial doubt about its ability to continue as a going concern. The filing also discloses material weaknesses in internal controls and significant related-party transactions, including the formation of Serephon LLC and a $2.05 million private placement. The going concern warning is the dominant risk factor here — it means the company may not survive the next twelve months without additional capital or a dramatic improvement in operations.
How filings like this one have moved
In the 30 days to Oct 13, 2026, 36.5% of the 995 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZEOX was trading at $1.15 on OTC in the Life Sciences sector, with a market capitalization of approximately $9M. The 52-week trading range was $0.97 to $2.99. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.